获得的1号染色体复制数和结构变异的多原子映射,以确定多发性骨髓瘤的治疗脆弱性
Eileen M Boyle1, Patrick Blaney1,2, James H Stoeckle1
1Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
概括
多发性骨髓瘤中的1号染色体副本数异常 (CNAs) 有着不同的影响. 全臂1q的增加通过改变基因表达和通路来推动不良结果,提供潜在的治疗点.
科学领域:
- 基因组学就是基因组学.
- 癌症生物学 癌症生物学
- 骨髓瘤研究 骨髓瘤研究
背景情况:
- 染色体1 (chr1) 副本数异常 (CNAs) 和结构变异 (SVs) 在新诊断的多发性髓瘤 (NDMM) 中很常见.
- 这些chr1变化对患者的结果有不同的影响,但根本的驱动因素尚未得到充分理解.
研究的目的:
- 在NDMM中全面分析chr1分子变异.
- 研究这些变异对基因表达和细胞通路的影响.
- 确定与chr1变化相关的遗传驱动因素和预后标记.
主要方法:
- 采用了多原子方法,包括CRISPR查,CNAs和SVs的基因映射,甲基化分析,基因表达概况和突变分析.
- 使用CRISPR识别了对chr1.1的功能依赖.
- 进行基因组丰富分析以了解途径的改变.
主要成果:
- 确定了两种不同的增益群:局限基因表达变化和中性预后的焦点增益,以及具有显著基因表达变化,复杂遗传学和不良预后的全臂增益.
- 在chr1.1上确定了7个删除区域,9个增益区域,3个染色体变 (CT) 事件和2个模板插入 (TI) 事件.
- 1q基因的低甲基化和显著的表达变化,包括代谢过程,亡性抵抗,MAPK信号和转录因子上调,与全臂增益和不良预后有关.
结论:
- 在chr1的遗传复杂性显著影响多发性骨髓瘤的临床表型.
- 1q的全臂增长代表了一个关键的预后组,它放松了多个途径的调节.
- 这些与全臂1q增长相关的放松调节途径可能对多发性骨髓瘤患者构成治疗漏洞.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.1K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
